|Podcasts|February 6, 2020

Episode 49: Navigate Emerging Markets with Data Science

Author(s)Christen Harm, Elaine Quilici

Pharm Exec speaks with Nigel Breakwell and Ben Randal, co-founders of Dot I/O Health. Nigel and Ben talk about how they’re using data science in the health and life sciences industries to help clients navigate emerging markets.

Pharm Exec speaks with Nigel Breakwell and Ben Randal, co-founders of Dot I/O Health. Nigel and Ben talk about how they’re using data science in the health and life sciences industries to help clients navigate emerging markets.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010

ByNicholas Jacobus

June 19th 2026

Episode 49: Navigate Emerging Markets with Data Science

Related Content

Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration

Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts

Pharmaceutical Executive Daily: AbbVie Acquires Apogee Therapeutics for $10.9 Billion

Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010

Trending on PharmExec

Reading Between the Lines: Closing the T1D Misdiagnosis Gap

EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval

The New Healthy Aging Imperative and What It Means for Pharma

Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics

FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer